Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of MDX-060 (iratumumab) in Relapsed or Refractory Anaplastic Large Cell Lymphoma
2005-005547-26Phase 2Completed
- Sponsor
- Medarex, Inc.
- Start
- Feb 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iratumumab in anaplastic large cell lymphoma (ALCL), sponsored by Medarex, Inc. Primary endpoint: Objective response rate at Day 50. Started Feb 2006; status: completed.
02
Drugs
iratumumab
03
Conditions
anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on 2005-005547-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005547-26.